Advances in research on potential inhibitors of multiple myeloma

被引：3

作者：

Tang, Guoyuan ^{[1
]}

Huang, Shan ^{[2
,3
]}

Luo, Ji ^{[4
,5
]}

Wu, Yingmiao ^{[4
,5
]}

Zheng, Shuai ^{[4
,5
]}

Tong, Rongsheng ^{[1
,6
]}

Zhong, Ling ^{[4
,5
,7
]}

Shi, Jianyou ^{[1
,6
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China

[2] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China

[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China

[4] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ctr Med Genet, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Sichuan, Peoples R China

[5] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China

[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm,Personalized Drug Therapy Key Lab Sichu, Chengdu 610072, Sichuan, Peoples R China

[7] Chinese Acad Sci, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 262卷

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

Multiple myeloma; Drug resistance; Potential drugs; Structure-activity relationships; UBIQUITIN-PROTEASOME-SYSTEM; TOLL-LIKE RECEPTORS; TARGETED PROTEIN-DEGRADATION; DRUG-RESISTANCE; DEUBIQUITINATING ENZYMES; NEDD8-ACTIVATING ENZYME; CELL-PROLIFERATION; KINASE; SUPPRESSES; ACTIVATION;

D O I：

10.1016/j.ejmech.2023.115875

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.

引用

页数：19

共 50 条

[21] Proteasome inhibitors for multiple myeloma
Okazuka, Kiyoshi
Ishida, Tadao
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 785 - 792
[22] Proteasome Inhibitors in Multiple Myeloma
Anderson, Kenneth C.
SEMINARS IN ONCOLOGY, 2009, 36 (02) : S20 - S26
[23] Recent advances in multiple myeloma immunotherapy
Ruffini, PA
Biragyn, A
Kwak, LW
BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (03) : 129 - 132
[24] Recent Advances in Nanotherapeutics for Multiple Myeloma
Iannazzo, Daniela
Ettari, Roberta
Giofre, Salvatore
Eid, Ali H.
Bitto, Alessandra
CANCERS, 2020, 12 (11) : 1 - 16
[25] Advances in multiple myeloma and spine disease
Latif, Tahir
Hussein, Mohamad A.
CLINICAL LYMPHOMA & MYELOMA, 2005, 6 (03): : 228 - 233
[26] Recent advances in the management of multiple myeloma
Kumar, Lalit
Verma, Rakesh
Radhakrishnan, Venkat Raman
NATIONAL MEDICAL JOURNAL OF INDIA, 2010, 23 (04): : 210 - 218
[27] Recent advances in the treatment of multiple myeloma
Jung, Sung-Hoon
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (04): : 245 - 252
[28] Advances in oral therapy for multiple myeloma
Morgan, GJ
Krishnan, B
Jenner, M
Davies, FE
LANCET ONCOLOGY, 2006, 7 (04): : 316 - 325
[29] Recent advances in the management of multiple myeloma
Munshi, NC
SEMINARS IN HEMATOLOGY, 2004, 41 (02) : 21 - 26
[30] Advances in the pathogenesis and diagnosis of multiple myeloma
Chesi, M.
Bergsagel, P. L.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 : 108 - 114

← 1 2 3 4 5 →